SHSvetlana Hamm

Svetlana Hamm

*This is an algorithmically generated author record based on publicly available information.

Svetlana Hamm has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Casein Kinase 1D Encodes a Novel Drug Target in Hedgehog—GLI-Driven Cancers and Tumor-Initiating Cells Resistant to SMO Inhibition

    by Elisabeth Peer, Sophie Karoline Aichberger, Filip Vilotic, Wolfgang Gruber, Thomas Parigger, Sandra Grund-Gröschke, Dominik Patrick Elmer, Florian Rathje, Andrea Ramspacher, Mirko Zaja, et al.

    (1) Background: Aberrant activation of the hedgehog (HH)—GLI pathway in stem-like tumor-initiating cells (TIC) is a frequent oncogenic driver signal in various human malignancies. Remarkable efficacy of anti-HH therapeutics led to the approval of HH inhibitors targeting the key pathway effector smoothened (SMO) in basal cell carcinoma and acute myeloid leukemia. However, frequent development of drug resistance and severe adverse effects of SMO inhibitors pose major challenges that require alternative treatment strategies targeting HH—GLI in TIC downstream of SMO. We therefore investigated members of the casein kinase 1 (CSNK1) family as novel drug targets in HH—GLI-driven malignancies. (2) Methods: We genetically and pharmacologically inhibited CSNK1D in HH-dependent cancer cells displaying either sensitivity or resistance to SMO inhibitors. To address the role of CSNK1D in oncogenic HH signaling and tumor growth and initiation, we quantitatively analyzed HH target gene expression, performed genetic and chemical perturbations of CSNK1D activity, and monitored the oncogenic transformation of TIC in vitro and in vivo using 3D clonogenic tumor spheroid assays and xenograft models. (3) Results: We show that CSNK1D plays a critical role in controlling oncogenic GLI activity downstream of SMO. We provide evidence that inhibition of CSNK1D interferes with oncogenic HH signaling in both SMO inhibitor-sensitive and -resistant tumor settings. Furthermore, genetic and pharmacologic perturbation of CSNK1D decreases the clonogenic growth of GLI-dependent TIC in vitro and in vivo. (4) Conclusions: Pharmacologic targeting of CSNK1D represents a novel therapeutic approach for the treatment of both SMO inhibitor-sensitive and -resistant tumors.


  • Open Access

    Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)

    by Anne Catherine Bretz, Ulrike Parnitzke, Kerstin Kronthaler, Tobias Dreker, René Bartz, Frank Hermann, Astrid Ammendola, Tanja Wulff, Svetlana Hamm

    The efficacy of PD-(L)1 blockade depends on the composition of the tumor immune microenvironment (TIME) and is generally higher in tumors with pre-existing cytotoxic T cells (CTL) than in those with low CTL numbers. Nonetheless, a significant proportion of patients with pre-existing immunity fail to respond, indicating a therapeutic potential for combining PD-(L)1 blockade with additional immunomodulatory agents in both CTL-high and -low immune phenotypes. Here, we evaluated domatinostat (4SC-202), a class I-selective histone deacetylase (HDAC) inhibitor, for its effect on the TIME and its antitumoral efficacy using syngeneic mouse models with CTL-high or CTL-low tumors. Domatinostat was evaluated in PD-1 blockade-insensitive CTL-low (CT26) and CTL-high (C38) syngeneic models alone and in combination with different immune-inhibitory and -stimulatory approaches. Effects on the immunophenotype were assessed via flow cytometry and RNA-seq analyses. The changes in RNA-seq-based immune signatures determined in a murine setting were investigated in patient samples from the first-dose cohort of the SENSITIZE trial (NCT03278665) evaluating domatinostat combined with pembrolizumab in advanced-stage melanoma patients refractory/nonresponding to PD-1 blockade. Domatinostat increased the expression of antigen-presenting machinery (APM) genes and MHC class I and II molecules, along with CTL infiltration, in tumors of both immune phenotypes. In combination with PD-(L)1 blockade, domatinostat augmented antitumor effects substantially above the effects of single-agent therapies, displaying greater benefit in tumors with pre-existing CTLs. In this setting, the combination of domatinostat with agonistic anti-4-1BB or both PD-1 and LAG3 blockade further increased the antitumor efficacy. In CTL-low tumors, domatinostat enhanced the expression of genes known to reinforce immune responses against tumors. Specifically, domatinostat increased the expression of Ifng and genes associated with responses to pembrolizumab and nivolumab. Clinically, these findings were confirmed in patients with advanced melanoma treated with domatinostat for 14 days, who demonstrated elevated expression of APM and MHC genes, the IFNG gene, and the IFN-γ and pembrolizumab response signatures in individual tumor samples. In summary, these data suggest a promising potential of domatinostat in combination with immunotherapy to improve the outcome of refractory cancer patients.


  • 4SC-202: Epigenetic modulation to pave the way for checkpoint inhibition.

    by Hella Kohlhof, Svetlana Hamm, Tanja Wulff, Roland Baumgartner, Daniel Vitt

    11546 Background: 4SC-202 is an orally available, small molecule clinical stage epigenetic modulator. Epigenetic modifiers are known to bear the potency to enhance response rates of checkpoint inhibitors and broaden the number of indications by combination treatment. Methods: 4SC-202 was tested in cellular assays and in a syngenic mouse model to investigate its capacity for immune modulation and combination treatment with checkpoint inhibitors. Results: Preclinical data demonstrate that 4SC-202 has immune priming potency by up-regulation of i) tumor associated antigens, ii) ligands for NK cell recognition, iii) MHC and costimulatory molecules, and iv) down-regulation of immunosuppression via the suppression of IDO and arginase in tumor cells as well as in myeloid-derived suppressor cells. In contrast to Entinostat and SAHA, 4SC-202 is not toxic for immune cells. By sparing the immune cells and enhancing the immunogenicity of tumor cells, 4SC-202 enables the immune system to attack tumor cells and provides a rationale for the combination with checkpoint inhibitors. To translate these effects from in vitro to in vivo, 4SC-202 was tested in a syngenic colon carcinoma CT26 mouse model in monotherapy and in combination with anti-PD1 antibody. 4SC-202 inhibited the growth of CT26 tumors at clinically relevant doses and therefore confirmed the relevance of the immunomodulating capacity of 4SC-202 for the anti-tumoral effect. The combination treatment with anti-PD1 antibody demonstrated that 4SC-202 is able to sensitize tumors for treatment with checkpoint inhibitors in indications where checkpoint inhibitors alone are not active. Conclusions: As demonstrated in a phase I clinical trial in 24 patients with relapsed or refractory hematological malignancies, 4SC-202 was well tolerated and objective responses (1 CR, 1 PR) and disease stabilizations were observed in several patients. 4SC-202 is an ideal combination partner for checkpoint inhibitors due to its immune priming capacity, the excellent safety profile and the oral formulation which allows convenient application and flexible dosing schedules.


  • Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists

    by Svetlana Hamm, Sandra Rath, Susanne Michel, Roland Baumgartner

    Toll-like receptor (TLR)-mediated signaling is proposed as an immunotherapeutic target against tumorigenesis. Natural killer (NK) cells play a critical role in host defense against tumors. Specifically, formation of tumor metastasis in various organs can be suppressed by the local activity of NK cells. In this study, we present a novel TLR7 agonist (termed SC-1) that induces pro-inflammatory cytokines in human blood cells, activates NK cell function, and is highly efficient in preventing lung metastases in a pulmonary metastatic Renca model. Furthermore, a second compound (termed SC-2), acting as dual-specific TLR7 and TLR8 agonist, was evaluated with respect to its immunostimulatory and NK cell–activating capacities. The release of pro-inflammatory cytokines was shown to be even more pronounced with this compound. Additional experiments showed a significant up-regulation of activation marker CD69 on NK cells and increased cytolytic activity of peripheral blood cells compared to the effect of a monospecific TLR7 agonist SC-1. Normally, TLR7 and TLR8 are expressed on different immune cell subpopulations. TLR7 expression on antigen-presenting cells is detected in plasmacytoid dendritic cells, CD34+-derived dendritic cells, and B-cells, whereas TLR8 is mainly expressed on cells of the myeloid lineage, such as monocytes, macrophages, and myeloid dendritic cells. Therefore, a compound that activates both TLR7 and TLR8 would result in a highly efficient immune system activation and may give rise to an enhanced anti-tumor activity in vivo compared to that elicited by a monospecific TLR7 agonist.